In recent years, there has been an explosion of interest in how fibroblasts initiate, sustain,
and resolve inflammation across disease states. Fibroblasts contain heterogeneous subsets …

Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized
by the proliferation of fibroblasts and the accumulation of a large amount of extracellular …

Patients with progressive fibrosing interstitial lung diseases (PF-ILDs) carry a poor prognosis
and have limited therapeutic options. A hallmark feature is fibroblast resistance to apoptosis …

Idiopathic pulmonary fibrosis is a progressive fibrotic disorder with no cure that is
characterized by deterioration of lung function. Current FDA-approved drugs for IPF delay …

Idiopathic pulmonary fibrosis (IPF) is a chronic parenchymal lung disease characterized by
repetitive alveolar cell injury, myofibroblast proliferation, and excessive extracellular matrix …

Background We previously identified ezetimibe, an inhibitor of Niemann–Pick C1-like
intracellular cholesterol transporter 1 and European Medicines Agency-approved lipid …

Objective: This study was conducted to establish a rat model of acute exacerbation of
idiopathic pulmonary fibrosis (AE-IPF) using the combination of bleomycin (BLM) and …

Precision management of fibrotic lung diseases is challenging due to their diverse clinical
trajectories and lack of reliable biomarkers for risk stratification and therapeutic monitoring …

Abstract Systemic Sclerosis (SSc) hallmark is skin fibrosis, but up to 80% of the patients
have fibrotic involvement in the pulmonary system. Antifibrotic drugs which have failed in a …

Drug development for idiopathic pulmonary fibrosis (IPF) has been challenging due to
poorly understood disease etiology, unpredictable disease progression, highly …